Cellosaurus NCI-H929 (CVCL_1600)

Cell line name NCI-H929
Synonyms NCI H929; NCIH929; H929; H-929
Accession CVCL_1600
Resource Identification Initiative To cite this cell line use: NCI-H929 (RRID:CVCL_1600)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: MYC genetic alteration cell panel (ATCC TCP-1035).
Part of: RAS genetic alteration cell panel (ATCC TCP-1031).
Characteristics: Produces IgA kappa.
Doubling time: ~50 hours (Patent=US4892829, PubMed=2423157); ~70 hours (DSMZ).
Microsatellite instability: Stable (MSS) (Sanger).
Sequence variation: Heterozygous for NRAS p.Gly13Asp (PubMed=11157491; ATCC).
Omics: Deep exome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Derived from sampling site: Pleural effusion.
Disease Plasma cell myeloma (NCIt: C3242)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children: CVCL_M400 (NCI-H929B)
Sex of cell Female
Category Cancer cell line
STR profile Source(s): ATCC; Cosmic-CLP; DSMZ; ECACC

Markers:
AmelogeninX
CSF1PO10,11 (ATCC; DSMZ)
11 (Cosmic-CLP; ECACC)
D13S31712
D16S5399,13
D5S81811,12
D7S82010,12
TH019.3
TPOX8,11
vWA14,15
Publications

PubMed=2423157
Gazdar A.F., Oie H.K., Kirsch I.R., Hollis G.F.
Establishment and characterization of a human plasma cell myeloma culture having a rearranged cellular myc proto-oncogene.
Blood 67:1542-1549(1986)

Patent=US4892829
Gazdar A.F., Oie H.K.
Human plasma cell line having rearranged c-myc proto-oncogene.
Patent number US4892829, 09-Jan-1990

PubMed=8806089; DOI=10.1002/jcb.240630502
Gazdar A.F., Minna J.D.
NCI series of cell lines: an historical perspective.
J. Cell. Biochem. 63 Suppl. 24:1-11(1996)

PubMed=8806092; DOI=10.1002/jcb.240630505
Phelps R.M., Johnson B.E., Ihde D.C., Gazdar A.F., Carbone D.P., McClintock P.R., Linnoila R.I., Matthews M.J., Bunn P.A. Jr., Carney D.N., Minna J.D., Mulshine J.L.
NCI-Navy Medical Oncology Branch cell line data base.
J. Cell. Biochem. 63 Suppl. 24:32-91(1996)

PubMed=8943038; DOI=10.1073/pnas.93.24.13931
Bergsagel P.L., Chesi M., Nardini E., Brents L.A., Kirby S.L., Kuehl W.M.
Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma.
Proc. Natl. Acad. Sci. U.S.A. 93:13931-13936(1996)

PubMed=10087940; DOI=10.1016/S0165-4608(98)00157-5
Kuipers J., Vaandrager J.W., Weghuis D.O., Pearson P.L., Scheres J., Lokhorst H.M., Clevers H., Bast B.J.E.G.
Fluorescence in situ hybridization analysis shows the frequent occurrence of 14q32.3 rearrangements with involvement of immunoglobulin switch regions in myeloma cell lines.
Cancer Genet. Cytogenet. 109:99-107(1999)

PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2
Drexler H.G., Matsuo Y.
Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia.
Leuk. Res. 24:681-703(2000)

PubMed=11157491
Chesi M., Brents L.A., Ely S.A., Bais C., Robbiani D.F., Mesri E.A., Kuehl W.M., Bergsagel P.L.
Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma.
Blood 97:729-736(2001)

PubMed=16956823
Bataille R., Jego G., Robillard N., Barille-Nion S., Harousseau J.-L., Moreau P., Amiot M., Pellat-Deceunynck C.
The phenotype of normal, reactive and malignant plasma cells Identification of 'many and multiple myelomas' and of new targets for myeloma therapy.
Haematologica 91:1234-1240(2006)

PubMed=17171682; DOI=10.1002/gcc.20404
Lombardi L., Poretti G., Mattioli M., Fabris S., Agnelli L., Bicciato S., Kwee I., Rinaldi A., Ronchetti D., Verdelli D., Lambertenghi-Deliliers G., Bertoni F., Neri A.
Molecular characterization of human multiple myeloma cell lines by integrative genomics: insights into the biology of the disease.
Genes Chromosomes Cancer 46:226-238(2007)

PubMed=18647998; DOI=10.1093/jncimonographs/lgn011
Dib A., Gabrea A., Glebov O.K., Bergsagel P.L., Kuehl W.M.
Characterization of MYC translocations in multiple myeloma cell lines.
J. Natl. Cancer Inst. Monogr. 39:25-31(2008)

PubMed=18700954; DOI=10.1186/1755-8794-1-37
Ronchetti D., Lionetti M., Mosca L., Agnelli L., Andronache A., Fabris S., Deliliers G.L., Neri A.
An integrative genomic approach reveals coordinated expression of intronic miR-335, miR-342, and miR-561 with deregulated host genes in multiple myeloma.
BMC Med. Genomics 1:37-37(2008)

PubMed=19306352; DOI=10.1002/gcc.20660
Lionetti M., Agnelli L., Mosca L., Fabris S., Andronache A., Todoerti K., Ronchetti D., Deliliers G.L., Neri A.
Integrative high-resolution microarray analysis of human myeloma cell lines reveals deregulated miRNA expression associated with allelic imbalances and gene expression profiles.
Genes Chromosomes Cancer 48:521-531(2009)

PubMed=21173094; DOI=10.3324/haematol.2010.033456
Moreaux J., Klein B., Bataille R., Descamps G., Maiga S., Hose D., Goldschmidt H., Jauch A., Reme T., Jourdan M., Amiot M., Pellat-Deceunynck C.
A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines.
Haematologica 96:574-582(2011)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

Cross-references
Cell line collections ATCC; CRL-9068
BCRC; 60386
DSMZ; ACC-163
ECACC; 95050415
Cell line databases/resources CLDB; cl3661
CLDB; cl3662
CCLE; NCIH929_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
CCRID; 3111C0001CCC000360
Cosmic-CLP; 724825
GDSC; 724825
Ontologies BTO; BTO:0002416
CLO; CLO_0008127
EFO; EFO_0001221
Biological sample resources BioSample; SAMN03473361
Gene expression databases GEO; GSM143333
GEO; GSM290290
GEO; GSM887452
GEO; GSM888532
GEO; GSM1374767
GEO; GSM1670271
Polymorphism and mutation databases Cosmic; 720769
Cosmic; 724825
Cosmic; 759905
Cosmic; 760391
Cosmic; 760392
Cosmic; 886085
Cosmic; 888022
Cosmic; 1070716
Cosmic; 1424217
Cosmic; 2081399
Cosmic; 2302415
Cosmic; 2367293
Cosmic; 2391791